Connect Biopharma Holdings Limited
CNTBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 14, 2026 | Canaccord Genuity | Edward Nash | $7.00(+187%) | $2.44 | TheFly |
| Jul 9, 2026 | Oppenheimer | $8.00(+211%) | $2.57 | TheFly | |
| Jun 26, 2026 | Piper Sandler | $7.00(+238%) | $2.07 | TheFly | |
| Jun 18, 2026 | H.C. Wainwright | Brandon Folkes | $7.00(+237%) | $2.08 | StreetInsider |
| May 26, 2026 | Canaccord Genuity | Edward Nash | $6.00(+155%) | $2.35 | TheFly |
| May 21, 2026 | Cantor Fitzgerald | Olivia Brayer | $4.00(+73%) | $2.31 | TheFly |
| Dec 1, 2025 | Lake Street | Thomas Flaten | $9.00(+215%) | $2.86 | TheFly |
| May 5, 2022 | Piper Sandler | Joseph Catanzaro | $1.50(+83%) | $0.82 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Oct 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 2, 2026 |
| BTIG | maintain | Buy | Sep 30, 2026 |
| Oppenheimer | maintain | Outperform | Sep 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 17, 2026 |
| Canaccord Genuity | maintain | Buy | Sep 16, 2026 |
| BTIG | maintain | Buy | Sep 15, 2026 |
| Piper Sandler | upgrade | Neutral →Overweight | Jun 26, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 25, 2026 |
| BTIG | maintain | Buy | Apr 1, 2026 |
| BTIG | maintain | Buy | Mar 31, 2026 |
| BTIG | maintain | Buy | Nov 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 17, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 13, 2023 |
| SVB Leerink | maintain | Outperform | Feb 8, 2023 |
| Piper Sandler | downgrade | Overweight →Neutral | May 5, 2022 |
| SVB Leerink | maintain | Outperform | May 4, 2022 |
| SVB Leerink | maintain | Outperform | Jan 6, 2022 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.27| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.27 | $-0.31 | $2.7M | $743.3K |
| May 12, 2026 | $-0.34 | $-0.29 | $24.4K | $743.3K |
| Mar 31, 2026 | $-0.27 | $-0.30 | — | $538.00 |
| Nov 12, 2025 | $-0.04 | $-0.03 | — | $4.9K |
| Aug 13, 2025 | $-0.03 | $-0.22 | $48.0K | $21.3K |
| May 15, 2025 | $-0.03 | $-0.26 | — | $48.0K |
| Mar 31, 2025 | $-0.06 | $-0.26 | $260.1K | $20.9M |
| Sep 5, 2024 | $0.02 | $-0.03 | $3.3M | $2.9M |
News
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Volatility and Risk Inhibrx Biosciences has a
Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.
Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and …
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C.
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected for a period of at least one year from the date of this release – SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care f…
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month